

Table S1 Details of 31 patients treated with tigecycline in 19 literature for cUTI

Patient No.	Age, years	Sex	Risk factors	Sepsis	Causative pathogen	Prior antibiotic therapy	Tigecycline regimen			Response		Relapse	Follow-up
							Dose	Duration	Concomitant	Clinical	Microbiologic		
1 (2)	54	F	DM	NS	MDR AB	NS	100 mg q12h	17 days	None	Cure	Positive	NS	6 weeks
	64	M	DM	NS	ESBL <i>K. pneumoniae</i>	NS	100 mg q12h	11 days	None	Failure	Positive	Died	6 weeks
2 (9)	NS	M	Urinary catheter	NS	MDR <i>K. pneumoniae</i> E. aerogenes	NS	200 mg q24h	12 days	None	Cure	Positive	NS	12 days
3 (10)	53	F	Kidney and liver transplantation, urinary catheter	NS	MDR AB and VRE	LVX, P/T, VAN	100 mg q12h	14 days	None	Cure	Positive	Yes	3 months
4 (11)	25	F	chronic urinary reflux, lumbar meningomyelocele and paraparesis below the second lumbar segment	Yes	ESBL <i>E. coli</i>	LVX, P/T, CTX, AMK, MEM, LNZ, voriconazole	NS	13 days	None	Cure	Positive	NS	38 days
5 (12)	63	NS	NS	NS	NS	NS	100 mg q12h	4 days	None	Cure	Positive	NS	30 days (range, 3–89)
	49	NS	NS	NS	NS	NS	100 mg q12h	13 days	None	Cure	Positive	NS	30 days (range, 3–89)
	63	NS	NS	NS	<i>Acinetobacter</i>	NS	100 mg q12h	12 days	Col	Cure	Positive	NS	30 days (range, 3–89)
6 (13)	70	F	Pneumonia, urinary catheter	NS	PDR <i>K. pneumoniae</i>	Tigecycline, PMB	NS	10 days	Rifampin	Failure	Negative	Yes	1 year
7 (14)	39	F	Stem cell transplant	Yes	<i>K. pneumoniae</i>	IMI	100 mg q12h	14 days	None	Cure	NS	NS	3 weeks
8 (15)	67	M	Polyneuropathy	Yes	<i>K. pneumoniae</i>	IMI	100 mg q12h	7 days	None	Failure	Negative	NS	3 weeks
	44	M	Renal transplant, DM, chronic prostatitis	NS	ESBL <i>E. coli</i>	MEM	NS	42 days	None	Cure	Positive	NO	18 weeks, 5 months
9 (16)	66	F	ESRD	NS	ESBL <i>E. coli</i>	NS	NS	42 days	None	Cure	Positive	NO	6 weeks, 4 months
	63	M	Prostatitis	Yes	ESBL <i>E. coli</i>	CIP, DOX, CTX, NTF, MOX, ETP	100 mg q12h	14 days	None	Cure	Positive	NO	4 months
10 (17)	27	F	Renal transplant	Yes	MDR AB	IMI	50 mg/d	NS	None	Cure	Positive	NS	NS
11 (18)	76	M	Spinal stenosis, lumbar osteomyelitis with epidural abscess, CKD	Yes	MDR AB	NS	100 mg q12h	12 days	P/T, IMI, sulbactam	Failure	Negative	NS	19 days
12 (19)	70	F	Polymyositis, interstitial lung disease	NO	ESBL <i>E. coli</i>	CEL, CFM, LVX	100 mg/d	14 days, 7 days	None	Cure	Positive	NS	3 weeks
13 (20)	86	M	CKD, DM, HTN, prostatic hypertrophy	Yes	ESBL <i>E. coli</i>	CTX, P/T, MEM, ETP	100 mg q12h	25 days, 42 days	Fluconazole	Cure	Negative	NO	157 days
14 (21)	71	NS	Renal transplant, DM, urinary catheter	Yes	blaKPC-2-Producing <i>K. pneumoniae</i>	None	NS	21 days, 16 days	CST	Failure	Negative	Yes	NS
	50	NS	Renal transplant	None	blaKPC-2-Producing <i>K. pneumoniae</i>	None	NS	26 days, 21 days	MEM	Failure	Negative	Yes	NS
15 (22)	65	F	Bone marrow transplantation	Yes	CRKP	NS	200 mg/d	11 days	P/T	Failure	Positive	NS	NS
	60	F	Cardiac surgery	Yes	CRKP	NS	200 mg/d	6 days	IMI	Cure	NS	NS	NS
	34	M	Multiple trauma	Yes	CRKP	NS	200 mg/d	8 days	None	Cure	NS	NS	NS
	80	M	Ulcerative colitis, abdominal surgery	Yes	CRKP	NS	200 mg/d	9 days	None	Cure	Negative	NS	NS
	54	M	Non-Hodgkin lymphoma	Yes	CRKP	NS	100 mg/d	15 days	MEM	Cure	Positive	NS	NS
16 (23)	53	F	DM, stage 3 CKD, nephrolithiasis, right double-J ureteral stent	None	CRKP	VAN, P/T	200 mg, 100 mg q12h, then 200 mg q24h, then 100 mg q12h	17 days		Cure	Positive	None	14
17 (24)	54	M	Heart disease, alcoholic hepatitis, liver transplant	None	CRKP	NS	100 mg q12h	26 days	CST	Cure	Positive	None	NS
18 (25)	NS	NS	NS	None	CRAB	NS	50 mg q12h	14 days	NS	Cure	NS	NS	NS
	NS	NS	NS	None	CRAB	NS	100 mg q12h	14 days	NS	Cure	NS	NS	NS
19 (26)	59	F	DM, PAD, HTN, Urethro-vesical catheterization	None	<i>Myroides odoratimimus</i>	None	NS	NS	None	Cure	NS	NS	NS
	72	M	BPH, COPD	None	<i>Myroides odoratimimus</i>	None	NS	NS	None	Cure	NS	NS	NS

F, female; M, male; NS, not stated; DM, diabetes mellitus; ESRD, end stage renal disease; CKD, chronic kidney disease; HTN, hypertension; PAD, peripheral arterial disorder; BPH, benign prostate hyperplasia; COPD, chronic obstructive pulmonary disease; MDR, multidrug resistance; ESBL, extended-spectrum beta-lactamase; VRE, vancomycin-resistant enterococci; PDR, pandrug resistant; AB, *Acinetobacter baumannii*; CRKP, *Carbapenem Resistant Klebsiella Pneumoniae*; CRAB, *Carbapenem Resistant Acinetobacter baumannii*; KPC, *Klebsiella pneumoniae carbapenemase*; LVX, levofloxacin; VAN, vancomycin; P/T, piperacilin/tazobactam. AMK, amikacin; CTX, cefotaxime; MEM, meropenem. LNZ, linezolid; PMB, polymyxin B; IMI, imipenem; CIP, ciprofloxacin; DOX, doxycycline; CTX, ceftriaxone; NTF, nitrofurantoin; MOX, moxifloxacin; ETP, ertapenem; CEL, cephalixin; CFM, cefixime; CST, colistin.